<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Cardiac amyloidosis</title><meta name="description" content="is a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart&#x27;s atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.[1] The overall decrease in cardiac function leads to a plethora of symptoms.[2] This multisystem disease was often misdiagnosed, with a corrected..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="amyloid cardiomyopathy, heart amyloidosis, cardiac amyloid"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Cardiac_amyloidosis"/><meta property="og:title" content="Cardiac amyloidosis"/><meta property="og:description" content="is a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart&#x27;s atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.[1] The overall decrease in cardiac function leads to a plethora of symptoms.[2] This multisystem disease was often misdiagnosed, with a corrected..."/><meta property="og:url" content="https://grokipedia.com/page/Cardiac_amyloidosis"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Cardiac amyloidosis"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.480Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Cardiac amyloidosis"/><meta name="twitter:description" content="is a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart&#x27;s atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.[1] The overall decrease in cardiac function leads to a plethora of symptoms.[2] This multisystem disease was often misdiagnosed, with a corrected..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="7b3f54c7f6b2a8a489901408f2f6031b-ba97603aeff3cab4-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=7b3f54c7f6b2a8a489901408f2f6031b,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.7872449992842829,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiac-amyloidosis" class="transition-opacity hover:opacity-100 opacity-50">Cardiac amyloidosis</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#types-of-cardiac-amyloidosis" class="transition-opacity hover:opacity-100 opacity-50">Types of Cardiac Amyloidosis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#light-chain-al-cm" class="transition-opacity hover:opacity-100 opacity-50">Light chain (AL-CM)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#familial-attrm-cm" class="transition-opacity hover:opacity-100 opacity-50">Familial (ATTRm-CM)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#wild-type-attrwt-cm" class="transition-opacity hover:opacity-100 opacity-50">Wild-type (ATTRwt-CM)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#symptoms-and-signs" class="transition-opacity hover:opacity-100 opacity-50">Symptoms and signs</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiac-amyloidosis-1" class="transition-opacity hover:opacity-100 opacity-50">Cardiac Amyloidosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cause" class="transition-opacity hover:opacity-100 opacity-50">Cause</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#echocardiography" class="transition-opacity hover:opacity-100 opacity-50">Echocardiography</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ecgekg" class="transition-opacity hover:opacity-100 opacity-50">ECG/EKG</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#laboratory-tests" class="transition-opacity hover:opacity-100 opacity-50">Laboratory tests</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiac-biomarkers" class="transition-opacity hover:opacity-100 opacity-50">Cardiac biomarkers</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biopsies" class="transition-opacity hover:opacity-100 opacity-50">Biopsies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#catheterization" class="transition-opacity hover:opacity-100 opacity-50">Catheterization</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiac-magnetic-resonance-imaging" class="transition-opacity hover:opacity-100 opacity-50">Cardiac magnetic resonance imaging</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#scintigraphyradionuclide-imaging" class="transition-opacity hover:opacity-100 opacity-50">Scintigraphy/radionuclide imaging</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mass-spectrometry" class="transition-opacity hover:opacity-100 opacity-50">Mass spectrometry</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatments" class="transition-opacity hover:opacity-100 opacity-50">Treatments</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#light-chain-al-cm-treatment" class="transition-opacity hover:opacity-100 opacity-50">Light chain (AL-CM) Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#familial-attrm-cm-treatment" class="transition-opacity hover:opacity-100 opacity-50">Familial (ATTRm-CM) Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#wild-type-attrwt-cm-treatment" class="transition-opacity hover:opacity-100 opacity-50">Wild-type (ATTRwt-CM) Treatment</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prognosis" class="transition-opacity hover:opacity-100 opacity-50">Prognosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="cardiac-amyloidosis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Cardiac amyloidosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">is a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart&#x27;s atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The overall decrease in cardiac function leads to a plethora of symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This multisystem disease was often misdiagnosed, with a corrected analysis only during autopsy, although it remains underdiagnosed despite advancements in diagnostic technologies that enable earlier detection. It is increasingly recognized, particularly the transthyretin (ATTR) forms, which are prevalent in older adults and contribute significantly to heart failure with preserved ejection fraction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Cardiac amyloidosis has multiple subtypes including light chain (AL), hereditary transthyretin (ATTRm), and wild-type transthyretin (ATTRwt).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> One of the most studied types is light chain cardiac amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Prognosis depends on the extent of the deposits in the body and the type of amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Disease-modifying treatments targeting amyloid production have been approved for AL and ATTR types, with ongoing research into additional therapies for heart failure and disease progression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h1 id="types-of-cardiac-amyloidosis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Types of Cardiac Amyloidosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">The multiple subtypes of cardiac amyloidosis have varying epidemiological, diagnostic, and prognostic characteristics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="light-chain-al-cm" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Light chain (AL-CM)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">This relatively rare form of cardiac amyloidosis occurs in an estimated six to ten cases per 1,000,000 people.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_22qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This subtype usually affects males over the age of 60<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> and is rapidly progressive. Pathogenesis of this form is due to the aggregation of immunoglobulin lambda light chains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> These chains are created by an abnormal expansion of plasma cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Over time, these light chains deposit into the interstitial tissue within the myocardium.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Diagnostic tests include serum and urine electrophoresis,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> laboratory testing for the determination of elevated levels of troponin and BNP, and ECGs showing low QRS voltages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h3 id="familial-attrm-cm" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Familial (ATTRm-CM)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">This type is caused by mutations of proteins involved in amyloid formation, including transthyretin (TTR), fibrinogen, apolipoprotein A1, or apolipoprotein A2. Due to the multiple number of potential genetic causes the incidence of this form is variable. The vast majority of familial cardiac amyloidosis still present after the age of 60.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> A common mutation is the TTR gene mutation Val122Ile.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> It is estimated that 3.5â€“4% of African Americans in the United States have the Val122Ile mutation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This type of amyloidosis can be identified by genetic testing for protein mutation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Diagnosis can often be made non-invasively with genetic testing confirming a pathogenic TTR mutation and positive cardiac scintigraphy (grade 2-3 uptake on Tc-99m-PYP or DPD scan); biopsy with histological evaluation is reserved for equivocal cases or to rule out AL amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> In this histological evaluation special stains are utilized to visualize the amyloid deposits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> One such stain is Congo red, which binds specifically to the amyloid deposit and can be characterized by various lighting methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Under polarized light, the amyloid deposits show pathognomonic apple green birefringence, and under plain light the deposits will appear a light salmon pink color.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Familial amyloidosis symptoms are centered around neuropathological and cardiac problems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Cardiac manifestations of the TTR mutation present more often in the United States.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="wild-type-attrwt-cm" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Wild-type (ATTRwt-CM)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">This type involves the wild-type (non-mutated) transthyretin protein that misfolds with age and leads to the development of TTR deposits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_24qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> It usually affects males over 70 years with the manifestation of carpal tunnel syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Diagnosis can be made non-invasively with cardiac scintigraphy showing grade 2 or 3 uptake and absence of monoclonal proteins, confirming ATTRwt after ruling out AL and hereditary ATTR; it is a diagnosis of exclusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_64qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Biopsy is not routinely required but can rule out other subtypes if needed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Non-invasive imaging such as Tc-99m bone scintigraphy is pivotal for ATTRwt diagnosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> This type is often misdiagnosed. However, greater use of cardiac magnetic resonance has increased the rate of diagnosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The severity of the disease tends to be less than the light chain variant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This is due to the amount of time that it takes to accumulate the amyloid depositions being longer in the wild-type variant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="symptoms-and-signs" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Symptoms and signs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Symptoms of cardiac amyloidosis are a combination of heart failure and amyloid deposition in various other organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_25qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Amyloid deposition in the heart causes restrictive diastolic heart failure that progresses to systolic heart failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiac manifestations include:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Dyspnea on exertion<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_226qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Peripheral edema and ascites<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_246qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Pericardial effusion<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_266qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Arrhythmias (secondary to disruption of the normal electrical system of the heart)
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Atrial arrhythmias (such as atrial fibrillation)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2a86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">First/second degree heart blocks<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2i86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
</ul>
</li>
<li class="text-[1em]">Syncope<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2a6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Elevated neck veins and jugular venous pressure<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></li>
<li class="text-[1em]">Myocardial ischemia/Angina (secondary to amyloid deposition in the small arteries of the heart)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2e6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Myocardial oxygen demand is increased in patients with cardiac amyloidosis, regardless of changes to coronary perfusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2ke6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></li>
</ul>
</li>
<li class="text-[1em]">Absence of third (S3) and fourth (S4) heart sounds<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2g6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">For patients with light-chain amyloidosis, there can be depositions of amyloid into numerous different organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Deposition of amyloid into other organs makes the diagnosis of cardiac amyloidosis difficult as these extracardiac manifestations mask the diagnosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Extracardiac manifestations include:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Macroglossia<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_127qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Periorbital bruising<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_147qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Thromboembolisms<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_167qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Symmetric sensory neuropathy (e.g., painful paresthesias in the lower limbs or hands)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_187qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></li>
<li class="text-[1em]">Postural hypotension (secondary to autonomic neuropathy)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1a7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Nephrotic syndrome (secondary to free light chain damage to the kidneys/deposition of amyloid in the kidneys)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1c7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">In ATTR amyloidosis, common extracardiac features include bilateral carpal tunnel syndrome and lumbar spinal stenosis, often preceding cardiac involvement by several years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<h1 id="cardiac-amyloidosis-1" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Cardiac Amyloidosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="cause" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Cause<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The general cause of cardiac amyloidosis is the misfolding of a specific protein precursor depending on the amyloidosis type. Protein precursors include immunoglobulin light chains (for AL amyloidosis) and transthyretin (for ATTR amyloidosis, which can be hereditary due to mutations or wild-type associated with aging).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The misfolding of the protein causes it to have insoluble beta-pleated sheets,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> creating an amyloid. Amyloid, the aggregation, or clumping, of proteins, is resistant to degradation by the body. Amyloids are mostly fibrils, while also containing a P component, apolipoprotein, collagen, fibronectin, and laminin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_69qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The P component, a pentameric protein, stabilizes the fibrils of the amyloid, which reduces their clearance from the body.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Deposits of the amyloids can occur throughout the body, including the heart, liver, kidneys, spleen, adrenal glands, and bones. Deposits in the extracellular cardiac space can stiffen the heart, resulting in restriction of the ventricles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This restriction in ventricular motion results in a decreased ability for the heart to pump efficiently, leading to the various symptoms associated with cardiac amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="diagnosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="echocardiography" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Echocardiography<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Echocardiography</span> is a safe and non-invasive method that can be used to assess the structural and functional disease of the heart.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Amyloidosis presents with ventricle and valvular thickening, biatrial enlargement,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> restrictive filling pattern, with normal to mildly reduced systolic function<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> and decreased <span class="inline text-[1em] leading-7">diastolic filling</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> An echo can be used to evaluate for prognosis of the disease, measuring the different strains within the heart.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Cardiac amyloidosis produces specific alterations to the functionality of the heart. Echocardiography can be utilized to detect this specific pattern (relative preservation of the apical myocardium with decreased longitudinal strain in the mid and basal sections), which is 93% sensitive and 82% specific for cardiac amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Echocardiography can be used to help physicians with diagnosis, however, it can only be used for the suggestion of the disease, not the confirmation, unless it is late stage amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="ecgekg" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">ECG/EKG<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">ECGs</span> of patients with cardiac amyloidosis usually show a low voltage in the limb leads, with an unusual extreme right axis. There is usually a normal <span class="inline text-[1em] leading-7">P-wave</span>, however, it can be slightly prolonged. For patients with light-chain amyloidosis, the <span class="inline text-[1em] leading-7">QRS complex pattern</span> is skewed,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> with poor R-waves of the chest leads.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Holter ECGs</span> can be used to identify asymptomatic <span class="inline text-[1em] leading-7">arrhythmias</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">EKG</span> changes may be present, showing low voltage and conduction abnormalities like <span class="inline text-[1em] leading-7">atrioventricular block</span> or <span class="inline text-[1em] leading-7">sinus node</span> dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Atrial fibrillation (AF) is observed in up to 70% of patients at the time of diagnosis, and patients typically have controlled ventricular rates caused by concomitant conduction system disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h3 id="laboratory-tests" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Laboratory tests<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Laboratory tests including <span class="inline text-[1em] leading-7">urea</span> and <span class="inline text-[1em] leading-7">creatinine levels</span>, <span class="inline text-[1em] leading-7">liver enzymes</span>, glucose, <span class="inline text-[1em] leading-7">thyroid function</span>, <span class="inline text-[1em] leading-7">full blood count</span>, and clotting tests. The analysis of serum and urine for presence of <span class="inline text-[1em] leading-7">monoclonal immunoglobulin</span> is also done through <span class="inline text-[1em] leading-7">immunofixation</span> for detection of the monoclonal band. Presence of the monoclonal band would be consistent with light chain amyloidosis. For light chain amyloidosis, <span class="inline text-[1em] leading-7">serum immunoglobulin free light chain assay</span> can be used for diagnosis and following of the amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ieabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In light-chain amyloidosis, a low <span class="inline text-[1em] leading-7">paraprotein level</span> can be present.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_meabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h3 id="cardiac-biomarkers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cardiac biomarkers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">There are two main cardiac biomarkers used in the assessment of cardiac amyloidosis, <span class="inline text-[1em] leading-7">troponin</span> and <span class="inline text-[1em] leading-7">N-terminal proBNP.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> As expected, with cardiac damage and dysfunction, there can be an elevation of these markers in patients with cardiac amyloidosis. These markers have been incorporated into the various staging/scoring systems used by physicians to determine severity of the disease and prognosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h3 id="biopsies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Biopsies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Extracardiac biopsies of tissues of the kidney, liver, peripheral nerve, or abdominal fat can be used to confirm the presence of amyloid deposits. Amyloid deposits in biopsy samples are confirmed through the use of <span class="inline text-[1em] leading-7">Congo red dye</span>, which produces a green birefringence when viewed under polarized light. <span class="inline text-[1em] leading-7">Sirius red staining</span> or <span class="inline text-[1em] leading-7">electron microscopy</span> examination can also be done. The determination of the type of amyloid can be done by <span class="inline text-[1em] leading-7">immunohisto-labeling</span> techniques as well as <span class="inline text-[1em] leading-7">immunofluorescence</span> staining.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For light-chain amyloidosis patients, bone marrow biopsies could be conducted to determine the baseline percentage of plasma cells and to rule out <span class="inline text-[1em] leading-7">multiple myeloma</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h3 id="catheterization" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Catheterization<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Right heart catheterization</span> is the test used to test for elevated diastolic <span class="inline text-[1em] leading-7">ventricular pressures</span>. This test is more invasive and would be performed after inconclusive <span class="inline text-[1em] leading-7">endomyocardial biopsy</span> samples.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="cardiac-magnetic-resonance-imaging" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cardiac magnetic resonance imaging<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Cardiac magnetic resonance</span> (CMR) is capable of measuring the thickness of different areas of the heart. This can be used for quantification of the deposits in the heart.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> CMR also shows the characterization of <span class="inline text-[1em] leading-7">myocardial tissue</span> through patterns of <span class="inline text-[1em] leading-7">gadolinium</span> enhancements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> However, none of the CMR technique is able to differentiate ATTR-CM and AL-CM definitely.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_biqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For AL-CM, 68% of them have symmetrical and concentric <span class="inline text-[1em] leading-7">left ventricular hypertrophy</span>. On the other hand, for ATTR-CM, 79% of them have asymmetrical left ventricular hypertrophy and 18% of them have symmetrical and concentric left ventricular hypertrophy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In <span class="inline text-[1em] leading-7">T1-weighted imaging</span>, edema in the heart can be detected with a high T1 signal. Meanwhile, enlargement of heart cells will reduce the T1 signal. Using T1 signal, Extracellular volume (ECV) is useful to determine the degree of amyloid deposition around the heart cells and detect the regression of amyloid deposits after treatment. ECV is higher in ATTR-CM than in AL-CM.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In T2-weighted imaging, the T2 signal is increased in acute myocarditis (inflammation of heart muscles), and <span class="inline text-[1em] leading-7">myocardial infarction</span> (heart attack). T2 signal is also increased in AL-CM and ATTR-CM but the signal is greater in AL-CM before starting chemotherapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Late gadolinum enhancement</span> (LGE) can determine the severity of deposition of amyloid in heart tissue. The higher the LGE signal, the more severe the heart involvement. It can be divided into three stages: no LGE, sub<span class="inline text-[1em] leading-7">endocardial</span> LGE, and full-thickness (transmural) LGE.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h3 id="scintigraphyradionuclide-imaging" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Scintigraphy/radionuclide imaging<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Scintigraphy</span> can be used to measure the extent and distribution of the amyloid throughout the body, including the liver, kidney, spleen, and heart.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> A <span class="inline text-[1em] leading-7">radiolabelled</span> serum amyloid P component can be administered to a patient <span class="inline text-[1em] leading-7">intravenously</span> and the P component pools to the amyloid deposit proportional to the size of the deposit. The labeling of the P component can then be pictured by a <span class="inline text-[1em] leading-7">gamma camera</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_blqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Technetium-labeled bone tracer scintigraphy (e.g., 99mTc-PYP or 99mTc-DPD) can reliably diagnose transthyretin (ATTR) cardiac amyloidosis, with certain scanning methods having greater than 99% sensitivity and approximately 91% specificity when used in patients without monoclonal gammopathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> In this method, the radiolabeled technetium is injected into the body where it binds preferentially to ATTR amyloid deposits in the heart. A subsequent scan highlights the uptake, graded from 0 to 3, with grade 2-3 uptake in the absence of light-chain amyloidosis allowing non-invasive definitive diagnosis of ATTR-CA (previously requiring endomyocardial biopsy).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> As of 2025, consensus guidelines reaffirm the role of 99mTc-PYP scintigraphy as a key diagnostic tool for ATTR-CA.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Emerging pan-amyloid tracers, such as I-evuzamitide, show promise for broader detection across amyloid types, with early data indicating 100% sensitivity and specificity for cardiac amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<h3 id="mass-spectrometry" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mass spectrometry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Mass spectrometry</span> can be used to determine whether the protein is light-chain or familial amyloidosis by identifying the <span class="inline text-[1em] leading-7">protein subunit</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<h1 id="treatments" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Treatments<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Treatments differ according to the type of amyloidosis present.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The majority of treatment is aimed at preserving heart function and treating heart failure symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h3 id="light-chain-al-cm-treatment" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Light chain (AL-CM) Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Since the cause of this subtype of cardiac amyloidosis is the excessive production of free light chains, the major goal of treatment is the reduction in concentration of light chains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> For light-chain amyloidosis, the use of FLC assays and NT-proBNP levels can be used to monitor the progression of amyloidosis and any response to treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> One of the major routes to decrease the production of these excess light chains is to kill the abnormal cells that are producing them.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Chemotherapeutic agents such as <span class="inline text-[1em] leading-7">melphalan</span> or <span class="inline text-[1em] leading-7">bortezomib</span> can be used to kill off the abnormal cell line that is producing the free light chains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Following chemotherapy, a <span class="inline text-[1em] leading-7">bone marrow transplant</span> can be utilized to restore the normal cell lines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Medications such as ixazomib, carfilzomib, daratumumab, and elotuzumab are incorporated into standard regimens, including the FDA-approved daratumumab-based quadruplet therapy (daratumumab, cyclophosphamide, bortezomib, and dexamethasone) as first-line treatment for AL amyloidosis since 2021.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ipabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> New data suggests that orthotopic heart transplant followed by melphalan and stem cell transplant produces results similar to non cardiac amyloidosis indicated heart transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> To treat complications, medications can be prescribed including <span class="inline text-[1em] leading-7">midodrine</span> for <span class="inline text-[1em] leading-7">autonomic neuropathy</span>, <span class="inline text-[1em] leading-7">amiodarone</span> for patients with <span class="inline text-[1em] leading-7">atrial fibrillation</span> to prevent <span class="inline text-[1em] leading-7">arrhythmias</span>, and <span class="inline text-[1em] leading-7">warfarin</span> used after a cardioembolic episode.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h3 id="familial-attrm-cm-treatment" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Familial (ATTRm-CM) Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In recent years there have been developments in the treatment of Familial/Transthyretin cardiac amyloidosis including methods to suppress transthyretin production, stabilize amyloid fibrils, and medications that can destroy already existing fibrils.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> For familial amyloidosis, <span class="inline text-[1em] leading-7">ACE-inhibitors</span> and beta-blockers can be prescribed if there is no autonomic neuropathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Suppression of transthyretin production:</strong> liver transplantation and medications that decreases the activity of the transthyretin genes (<span class="inline text-[1em] leading-7">patisiran</span>, <span class="inline text-[1em] leading-7">inotersen</span>, and <span class="inline text-[1em] leading-7">vutrisiran</span>).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Vutrisiran was FDA-approved in March 2025 for ATTR-CM.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2qqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> In patients with familial transthyretin mutations, liver transplantation can provide the body with a source of normal transthyretin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3aqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> By changing the source of transthyretin from the original liver that contains the mutated transthyretin to a healthy liver, there will be no more production of the abnormal protein.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3qqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> However, liver transplant does not reverse the disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> The goal of liver transplant is to prevent additional amyloid deposition and prevent new symptoms/complications from happening.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> These medications bind to the mRNA of transthyretin and prevent the production of the transthyretin protein, thus decreasing the overall amount of transthyretin that can accumulate in the body.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></li>
<li class="text-[1em]"><strong>Stabilization of abnormal transthyretin:</strong> There are medications that can stabilize the normally folded transthyretin, preventing misfolding and subsequent amyloid deposition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> These medications include <span class="inline text-[1em] leading-7">Tafamidis</span>, the <span class="inline text-[1em] leading-7">NSAID</span> <span class="inline text-[1em] leading-7">Diflunisal</span>, and acoramidis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2sqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Tafamidis is a medication that binds to transthyretin and keeps it in its normal shape, stopping it from aggregating into amyloid fibrils.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Acoramidis, formerly known as AG10, was FDA-approved in November 2024 for ATTR-CM.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3sqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Diflunisal works in a similar manner to tafamidis in its ability to bind to and stabilize Transthyretin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></li>
<li class="text-[1em]"><strong>Destruction of existing amyloid fibrils:</strong> There are multiple medications that show amyloid destroying properties, <span class="inline text-[1em] leading-7">Doxycycline</span>, <span class="inline text-[1em] leading-7">Tauro-ursodeoxy-cholic acid (TUDCA)</span>, and monoclonal antibodies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1uqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></li>
</ul>
<h3 id="wild-type-attrwt-cm-treatment" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Wild-type (ATTRwt-CM) Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Treatments for wild-type transthyretin cardiac amyloidosis primarily focus on stabilizing transthyretin to prevent further amyloid deposition and managing heart failure symptoms, as there is no genetic mutation to target with suppression therapies. TTR stabilizers such as tafamidis (FDA-approved 2019) and acoramidis (FDA-approved 2024) are standard. Gene silencers like vutrisiran (FDA-approved 2025 for ATTR-CM, including wild-type) may also be used to reduce TTR production. Supportive care includes diuretics for congestion, and caution with ACE inhibitors or beta-blockers due to risk of hypotension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The use of <span class="inline text-[1em] leading-7">pacemakers</span> (both right ventricular pacing and biventricular pacing) or <span class="inline text-[1em] leading-7">implantable cardioverter defibrillators</span> remains questionable in cardiac amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<h2 id="prognosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Prognosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Overall prognosis is dependent on the extent of cardiac dysfunction. Worse outcomes have been seen when echocardiography shows left ventricular wall thickness, poor systolic function and severe diastolic dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Light chain (AL-CM) Prognosis:</strong> For light-chain amyloidosis early detection leads to best possibility of therapies prolonging the period of remission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> In contemporary cohorts (as of 2023), median survival is approximately 5 years, with 5-year survival up to 93% in patients achieving cardiac complete response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> In patients that undergo autologous stem cell transplant, median survival can exceed 10 years in responders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Staging systems have been developed to stratify severity of the disease, including the Mayo Biomarker Stage, which utilizes various biomarkers such as troponin I, troponin T, BNP, and NT-proBNP, and free light chain concentrations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_btqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Familial (ATTRm-CM) Prognosis:</strong> Due to the extensive number of variables involved in this subtype, prognosis varies depending on the specific type of familial cardiac amyloidosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Variables include the specific TTR mutation versus wild-type ATTR (ATTRwt), and age of onset of symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> In comparison to light chain amyloidosis, the ATTR subtypes (both mutant and wild-type) are generally slower to progress and have a more favorable prognosis untreated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> However, the Val122Ile mutation (common in individuals of African ancestry) has a median survival of approximately 3.4 years after diagnosis untreated, though treatment with stabilizers like tafamidis improves outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_auabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> A delay in recognition plays a major factor in reduced survival.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Wild-type (ATTRwt-CM) Prognosis:</strong> Wild-type transthyretin amyloidosis primarily affects older adults and has a median survival of 3.5 to 5 years from diagnosis if untreated. With tafamidis treatment, 5-year survival is approximately 55% as of 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Fikrle M, PaleÄek T, Kuchynka P, NÄ›meÄek E, BauerovÃ¡ L, Straub J, et al. (2013-02-01). <a href="https://doi.org/10.1016%2Fj.crvasa.2012.11.018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiac amyloidosis: A comprehensive review&quot;</a>. <em>Cor et Vasa</em>. <strong>55</strong> (1): e60 â€“ e75. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.crvasa.2012.11.018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.crvasa.2012.11.018</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0010-8650" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0010-8650</a>.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><strong>aa</strong></em> Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD (2012-04-24). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487372" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Updates in Cardiac Amyloidosis: A Review&quot;</a>. <em>Journal of the American Heart Association</em>. <strong>1</strong> (2): e000364. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1161%2FJAHA.111.000364" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1161/JAHA.111.000364</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2047-9980" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2047-9980</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487372" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3487372</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23130126" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23130126</a>.</span></div></li><li id="https://www.mdpi.com/2077-0383/14/13/4785" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2077-0383/14/13/4785" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2077-0383/14/13/4785</a></span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Falk RH, Alexander KM, et al. (2016-09-20). <a href="http://www.onlinejacc.org/content/68/12/1323" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy&quot;</a>. <em>Journal of the American College of Cardiology</em>. <strong>68</strong> (12): 1323â€“1341. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.jacc.2016.06.053" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.jacc.2016.06.053</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0735-1097" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0735-1097</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/27634125" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27634125</a>.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V, et al. (2018-01-01). &quot;Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions&quot;. <em>Current Problems in Cardiology</em>. <strong>43</strong> (1): 10â€“34. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.cpcardiol.2017.04.003" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.cpcardiol.2017.04.003</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0146-2806" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0146-2806</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29173805" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29173805</a>.</span></div></li><li id="https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016</a></span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Siddiqi OK, Ruberg FL (January 2018). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741539" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment&quot;</a>. <em>Trends in Cardiovascular Medicine</em>. <strong>28</strong> (1): 10â€“21. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.tcm.2017.07.004" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.tcm.2017.07.004</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1873-2615" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1873-2615</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741539" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5741539</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28739313" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28739313</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Manolis AS, Manolis AA, Manolis TA, Melita H (September 2019). <a href="https://dx.doi.org/10.1016/j.ejim.2019.07.022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cardiac amyloidosis: An underdiagnosed/underappreciated disease&quot;</a>. <em>European Journal of Internal Medicine</em>. <strong>67</strong> : 1â€“13. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ejim.2019.07.022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ejim.2019.07.022</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0953-6205" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0953-6205</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/31375251" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31375251</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:199388460" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">199388460</a>.</span></div></li><li id="https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022</a></span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ruberg FL, Berk JL (2012-09-04). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501197" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Transthyretin (TTR) Cardiac Amyloidosis&quot;</a>. <em>Circulation</em>. <strong>126</strong> (10): 1286â€“1300. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1161%2FCIRCULATIONAHA.111.078915" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1161/CIRCULATIONAHA.111.078915</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0009-7322" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0009-7322</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501197" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3501197</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22949539" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22949539</a>.</span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK580521/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK580521/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK580521/</a></span></div></li><li id="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792</a></span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Falk RH, Comenzo RL, et al. (25 September 1997). &quot;The Systemic Amyloidoses&quot;. <em>New England Journal of Medicine</em>. <strong>337</strong> (13): 898â€“909. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJM199709253371306" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJM199709253371306</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9302305" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9302305</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gertz MA, Dispenzieri A, Sher T (2014-10-14). &quot;Pathophysiology and treatment of cardiac amyloidosis&quot;. <em>Nature Reviews Cardiology</em>. <strong>12</strong> (2): 91â€“102. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnrcardio.2014.165" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nrcardio.2014.165</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1759-5002" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1759-5002</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25311231" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25311231</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:2080325" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2080325</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clemmensen TS, Soerensen J, Hansson N, Tolbod LP, Harms HJ, EiskjÃ¦r H, et al. (2018-11-06). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404209" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Myocardial Oxygen Consumption and Efficiency in Patients With Cardiac Amyloidosis&quot;</a>. <em>Journal of the American Heart Association</em>. <strong>7</strong> (21): e009974. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1161%2FJAHA.118.009974" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1161/JAHA.118.009974</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2047-9980" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2047-9980</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404209" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6404209</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30571379" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30571379</a>.</span></div></li><li id="https://www.jacc.org/doi/10.1016/j.jacc.2019.04.054" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacc.org/doi/10.1016/j.jacc.2019.04.054" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacc.org/doi/10.1016/j.jacc.2019.04.054</a></span></div></li><li id="https://doi.org/10.1136/heartjnl-2012-302037" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1136/heartjnl-2012-302037" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1136/heartjnl-2012-302037</a></span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hartnett, Jack; Jaber, Wael; Maurer, Mathew; Sperry, Brett; Hanna, Mazen; Collier, Patrick; Patel, Divyang R.; Wazni, Oussama M.; Donnellan, Eoin (October 2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543134" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Electrophysiological Manifestations of Cardiac Amyloidosis&quot;</a>. <em>JACC: CardioOncology</em>. <strong>3</strong> (4): 506â€“515. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.jaccao.2021.07.010" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.jaccao.2021.07.010</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543134" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8543134</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/34729522" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34729522</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:239554406" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">239554406</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, et al. (December 2018). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278059" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers&quot;</a>. <em>BMC Cardiovascular Disorders</em>. <strong>18</strong> (1) 221. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1186%2Fs12872-018-0952-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1186/s12872-018-0952-8</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1471-2261" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1471-2261</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278059" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6278059</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30509186" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30509186</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M (July 2020). <a href="http://www.nature.com/articles/s41569-020-0334-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Diagnostic imaging of cardiac amyloidosis&quot;</a>. <em>Nature Reviews Cardiology</em>. <strong>17</strong> (7): 413â€“426. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fs41569-020-0334-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/s41569-020-0334-7</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1759-5002" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1759-5002</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32042139" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32042139</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:211067205" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">211067205</a>.</span></div></li><li id="https://doi.org/10.1161/CIRCULATIONAHA.116.021612" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1161/CIRCULATIONAHA.116.021612" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1161/CIRCULATIONAHA.116.021612</a></span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. (2016-06-14). <a href="https://doi.org/10.1161%2FCIRCULATIONAHA.116.021612" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis&quot;</a>. <em>Circulation</em>. <strong>133</strong> (24): 2404â€“2412. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1161%2FCIRCULATIONAHA.116.021612" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1161/CIRCULATIONAHA.116.021612</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/11392%2F2415152" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11392/2415152</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/0009-7322" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">0009-7322</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/27143678" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27143678</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:7106253" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7106253</a>.</span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11701493/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11701493/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11701493/</a></span></div></li><li id="https://attralus.com/press-releases/attralus-presents-new-data-on-its-pan-amyloid-diagnostic-imaging-candidates-at-asnc-2025" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://attralus.com/press-releases/attralus-presents-new-data-on-its-pan-amyloid-diagnostic-imaging-candidates-at-asnc-2025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://attralus.com/press-releases/attralus-presents-new-data-on-its-pan-amyloid-diagnostic-imaging-candidates-at-asnc-2025</a></span></div></li><li id="https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-becomes-the-first-fda-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-becomes-the-first-fda-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-becomes-the-first-fda-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis</a></span></div></li><li id="https://investors.alnylam.com/press-release?id=28831" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.alnylam.com/press-release?id=28831" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.alnylam.com/press-release?id=28831</a></span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rocha A, Lobato L (April 2015). <a href="https://dx.doi.org/10.1002/lt.24150" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Reply: Liver transplantation in transthyretin amyloidosis: Issues and challenges&quot;</a>. <em>Liver Transplantation</em> : n/a. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Flt.24150" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/lt.24150</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1527-6465" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1527-6465</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25891323" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25891323</a>.</span></div></li><li id="https://bridgebio.com/news/attruby-acoramidis-a-near-complete-ttr-stabilizer-%25E2%2589%25A590-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-attr-cm-patients/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bridgebio.com/news/attruby-acoramidis-a-near-complete-ttr-stabilizer-%25E2%2589%25A590-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-attr-cm-patients/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bridgebio.com/news/attruby-acoramidis-a-near-complete-ttr-stabilizer-%25E2%2589%25A590-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-attr-cm-patients/</a></span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, <span class="inline text-[1em] leading-7">Connors LH</span>, et al. (September 2020). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758872" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis&quot;</a>. <em>Journal of Cardiac Failure</em>. <strong>26</strong> (9): 753â€“759. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.cardfail.2019.11.024" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.cardfail.2019.11.024</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1532-8414" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1532-8414</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758872" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7758872</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/31805416" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31805416</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK (March 2020). &quot;Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment&quot;. <em>The Canadian Journal of Cardiology</em>. <strong>36</strong> (3): 416â€“423. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.cjca.2019.11.039" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.cjca.2019.11.039</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1916-7075" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1916-7075</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32145868" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32145868</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:212638552" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">212638552</a>.</span></div></li><li id="https://www.jacc.org/doi/10.1016/j.jaccao.2022.08.009" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacc.org/doi/10.1016/j.jaccao.2022.08.009" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacc.org/doi/10.1016/j.jaccao.2022.08.009</a></span></div></li><li id="https://ashpublications.org/blood/article/144/7/790/516349/Patients-with-a-cardiac-complete-response-in-AL" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ashpublications.org/blood/article/144/7/790/516349/Patients-with-a-cardiac-complete-response-in-AL" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ashpublications.org/blood/article/144/7/790/516349/Patients-with-a-cardiac-complete-response-in-AL</a></span></div></li><li id="https://www.myamyloidosisteam.com/resources/whats-the-life-expectancy-with-hattr-amyloidosis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.myamyloidosisteam.com/resources/whats-the-life-expectancy-with-hattr-amyloidosis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.myamyloidosisteam.com/resources/whats-the-life-expectancy-with-hattr-amyloidosis</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10607607/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10607607/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10607607/</a></span></div></li><li id="https://www.jacc.org/doi/10.1016/j.jaccao.2024.12.005" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jacc.org/doi/10.1016/j.jaccao.2024.12.005" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jacc.org/doi/10.1016/j.jaccao.2024.12.005</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Cardiac_amyloidosis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh" id="_R_" async=""></script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Cardiac_amyloidosis\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Cardiac_amyloidosis\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Cardiac_amyloidosis\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T620c,"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"# Cardiac amyloidosis\n\nis a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart's atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.[1] The overall decrease in cardiac function leads to a plethora of symptoms.[2] This multisystem disease was often misdiagnosed, with a corrected analysis only during autopsy, although it remains underdiagnosed despite advancements in diagnostic technologies that enable earlier detection. It is increasingly recognized, particularly the transthyretin (ATTR) forms, which are prevalent in older adults and contribute significantly to heart failure with preserved ejection fraction.[](https://www.mdpi.com/2077-0383/14/13/4785) Cardiac amyloidosis has multiple subtypes including light chain (AL), hereditary transthyretin (ATTRm), and wild-type transthyretin (ATTRwt).[3] One of the most studied types is light chain cardiac amyloidosis.[2] Prognosis depends on the extent of the deposits in the body and the type of amyloidosis.[4] Disease-modifying treatments targeting amyloid production have been approved for AL and ATTR types, with ongoing research into additional therapies for heart failure and disease progression.[](https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016)[5][6]\n# Types of Cardiac Amyloidosis\n\nThe multiple subtypes of cardiac amyloidosis have varying epidemiological, diagnostic, and prognostic characteristics.[4]\n\n### Light chain (AL-CM)\n\nThis relatively rare form of cardiac amyloidosis occurs in an estimated six to ten cases per 1,000,000 people.[4] This subtype usually affects males over the age of 60[4] and is rapidly progressive. Pathogenesis of this form is due to the aggregation of immunoglobulin lambda light chains.[3] These chains are created by an abnormal expansion of plasma cells.[3] Over time, these light chains deposit into the interstitial tissue within the myocardium.[4] Diagnostic tests include serum and urine electrophoresis,[4] laboratory testing for the determination of elevated levels of troponin and BNP, and ECGs showing low QRS voltages.[2]\n\n### Familial (ATTRm-CM)\n\nThis type is caused by mutations of proteins involved in amyloid formation, including transthyretin (TTR), fibrinogen, apolipoprotein A1, or apolipoprotein A2. Due to the multiple number of potential genetic causes the incidence of this form is variable. The vast majority of familial cardiac amyloidosis still present after the age of 60.[4] A common mutation is the TTR gene mutation Val122Ile.[2] It is estimated that 3.5â€“4% of African Americans in the United States have the Val122Ile mutation.[4] This type of amyloidosis can be identified by genetic testing for protein mutation.[4] Diagnosis can often be made non-invasively with genetic testing confirming a pathogenic TTR mutation and positive cardiac scintigraphy (grade 2-3 uptake on Tc-99m-PYP or DPD scan); biopsy with histological evaluation is reserved for equivocal cases or to rule out AL amyloidosis.[](https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022) In this histological evaluation special stains are utilized to visualize the amyloid deposits.[7] One such stain is Congo red, which binds specifically to the amyloid deposit and can be characterized by various lighting methods.[7] Under polarized light, the amyloid deposits show pathognomonic apple green birefringence, and under plain light the deposits will appear a light salmon pink color.[7] Familial amyloidosis symptoms are centered around neuropathological and cardiac problems.[3] Cardiac manifestations of the TTR mutation present more often in the United States.[4]\n\n### Wild-type (ATTRwt-CM)\n\nThis type involves the wild-type (non-mutated) transthyretin protein that misfolds with age and leads to the development of TTR deposits.[2] It usually affects males over 70 years with the manifestation of carpal tunnel syndrome.[4] Diagnosis can be made non-invasively with cardiac scintigraphy showing grade 2 or 3 uptake and absence of monoclonal proteins, confirming ATTRwt after ruling out AL and hereditary ATTR; it is a diagnosis of exclusion.[](https://www.ncbi.nlm.nih.gov/books/NBK580521/) Biopsy is not routinely required but can rule out other subtypes if needed.[4] Non-invasive imaging such as Tc-99m bone scintigraphy is pivotal for ATTRwt diagnosis.[](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792) This type is often misdiagnosed. However, greater use of cardiac magnetic resonance has increased the rate of diagnosis.[2] The severity of the disease tends to be less than the light chain variant.[4] This is due to the amount of time that it takes to accumulate the amyloid depositions being longer in the wild-type variant.[4]\n## Symptoms and signs\n\nSymptoms of cardiac amyloidosis are a combination of heart failure and amyloid deposition in various other organs.[2] Amyloid deposition in the heart causes restrictive diastolic heart failure that progresses to systolic heart failure.[8]\n\nCardiac manifestations include: \n\n- Dyspnea on exertion[2]\n- Peripheral edema and ascites[2]\n- Pericardial effusion[2]\n- Arrhythmias (secondary to disruption of the normal electrical system of the heart) \n  - Atrial arrhythmias (such as atrial fibrillation)[2]\n  - First/second degree heart blocks[2]\n- Syncope[2]\n- Elevated neck veins and jugular venous pressure[9]\n- Myocardial ischemia/Angina (secondary to amyloid deposition in the small arteries of the heart)[2]\n  - Myocardial oxygen demand is increased in patients with cardiac amyloidosis, regardless of changes to coronary perfusion.[10]\n- Absence of third (S3) and fourth (S4) heart sounds[3]\n\nFor patients with light-chain amyloidosis, there can be depositions of amyloid into numerous different organs.[2] Deposition of amyloid into other organs makes the diagnosis of cardiac amyloidosis difficult as these extracardiac manifestations mask the diagnosis.[2] Extracardiac manifestations include: \n\n- Macroglossia[2]\n- Periorbital bruising[2]\n- Thromboembolisms[2]\n- Symmetric sensory neuropathy (e.g., painful paresthesias in the lower limbs or hands)[3]\n- Postural hypotension (secondary to autonomic neuropathy)[2]\n- Nephrotic syndrome (secondary to free light chain damage to the kidneys/deposition of amyloid in the kidneys)[2]\n\nIn ATTR amyloidosis, common extracardiac features include bilateral carpal tunnel syndrome and lumbar spinal stenosis, often preceding cardiac involvement by several years.[](https://www.jacc.org/doi/10.1016/j.jacc.2019.04.054)\n# Cardiac Amyloidosis\n\n## Cause\n\nThe general cause of cardiac amyloidosis is the misfolding of a specific protein precursor depending on the amyloidosis type. Protein precursors include immunoglobulin light chains (for AL amyloidosis) and transthyretin (for ATTR amyloidosis, which can be hereditary due to mutations or wild-type associated with aging).[2] The misfolding of the protein causes it to have insoluble beta-pleated sheets,[2] creating an amyloid. Amyloid, the aggregation, or clumping, of proteins, is resistant to degradation by the body. Amyloids are mostly fibrils, while also containing a P component, apolipoprotein, collagen, fibronectin, and laminin.[2] The P component, a pentameric protein, stabilizes the fibrils of the amyloid, which reduces their clearance from the body.[1] Deposits of the amyloids can occur throughout the body, including the heart, liver, kidneys, spleen, adrenal glands, and bones. Deposits in the extracellular cardiac space can stiffen the heart, resulting in restriction of the ventricles.[2] This restriction in ventricular motion results in a decreased ability for the heart to pump efficiently, leading to the various symptoms associated with cardiac amyloidosis.[4]\n## Diagnosis\n\n### Echocardiography\n\n[Echocardiography](Echocardiography \"Echocardiography\") is a safe and non-invasive method that can be used to assess the structural and functional disease of the heart.[4] Amyloidosis presents with ventricle and valvular thickening, biatrial enlargement,[4] restrictive filling pattern, with normal to mildly reduced systolic function[8] and decreased [diastolic filling](Diastole \"Diastole\").[4] An echo can be used to evaluate for prognosis of the disease, measuring the different strains within the heart.[4] Cardiac amyloidosis produces specific alterations to the functionality of the heart. Echocardiography can be utilized to detect this specific pattern (relative preservation of the apical myocardium with decreased longitudinal strain in the mid and basal sections), which is 93% sensitive and 82% specific for cardiac amyloidosis.[](https://doi.org/10.1136/heartjnl-2012-302037) Echocardiography can be used to help physicians with diagnosis, however, it can only be used for the suggestion of the disease, not the confirmation, unless it is late stage amyloidosis.[1]\n\n### ECG/EKG\n\n[ECGs](Electrocardiography \"Electrocardiography\") of patients with cardiac amyloidosis usually show a low voltage in the limb leads, with an unusual extreme right axis. There is usually a normal [P-wave](P_wave_\\(electrocardiography\\) \"P wave \\(electrocardiography\\)\"), however, it can be slightly prolonged. For patients with light-chain amyloidosis, the [QRS complex pattern](QRS_complex \"QRS complex\") is skewed,[1] with poor R-waves of the chest leads.[2]\n\n[Holter ECGs](Holter_monitor \"Holter monitor\") can be used to identify asymptomatic [arrhythmias](Heart_arrhythmia \"Heart arrhythmia\").[2]\n\n[EKG](Electrocardiogram \"Electrocardiogram\") changes may be present, showing low voltage and conduction abnormalities like [atrioventricular block](Atrioventricular_block \"Atrioventricular block\") or [sinus node](Sinus_node \"Sinus node\") dysfunction.[8] Atrial fibrillation (AF) is observed in up to 70% of patients at the time of diagnosis, and patients typically have controlled ventricular rates caused by concomitant conduction system disease.[11]\n\n### Laboratory tests\n\nLaboratory tests including [urea](Urea \"Urea\") and [creatinine levels](Renal_function \"Renal function\"), [liver enzymes](Liver_function_tests \"Liver function tests\"), glucose, [thyroid function](Thyroid_function_tests \"Thyroid function tests\"), [full blood count](Complete_blood_count \"Complete blood count\"), and clotting tests. The analysis of serum and urine for presence of [monoclonal immunoglobulin](Immunoglobulin_light_chain \"Immunoglobulin light chain\") is also done through [immunofixation](Immunofixation \"Immunofixation\") for detection of the monoclonal band. Presence of the monoclonal band would be consistent with light chain amyloidosis. For light chain amyloidosis, [serum immunoglobulin free light chain assay](Serum_free_light-chain_measurement \"Serum free light-chain measurement\") can be used for diagnosis and following of the amyloidosis.[1] In light-chain amyloidosis, a low [paraprotein level](Paraprotein \"Paraprotein\") can be present.[3]\n\n### Cardiac biomarkers\n\nThere are two main cardiac biomarkers used in the assessment of cardiac amyloidosis, [troponin](Troponin_T \"Troponin T\") and [N-terminal proBNP.](N-terminal_prohormone_of_brain_natriuretic_peptide \"N-terminal prohormone of brain natriuretic peptide\")[12] As expected, with cardiac damage and dysfunction, there can be an elevation of these markers in patients with cardiac amyloidosis. These markers have been incorporated into the various staging/scoring systems used by physicians to determine severity of the disease and prognosis.[12]\n\n### Biopsies\n\nExtracardiac biopsies of tissues of the kidney, liver, peripheral nerve, or abdominal fat can be used to confirm the presence of amyloid deposits. Amyloid deposits in biopsy samples are confirmed through the use of [Congo red dye](Congo_red \"Congo red\"), which produces a green birefringence when viewed under polarized light. [Sirius red staining](Sirius_Red \"Sirius Red\") or [electron microscopy](Electron_microscope \"Electron microscope\") examination can also be done. The determination of the type of amyloid can be done by [immunohisto-labeling](Immunohistochemistry_test \"Immunohistochemistry test\") techniques as well as [immunofluorescence](Immunofluorescence \"Immunofluorescence\") staining.[1]\n\nFor light-chain amyloidosis patients, bone marrow biopsies could be conducted to determine the baseline percentage of plasma cells and to rule out [multiple myeloma](Multiple_myeloma \"Multiple myeloma\").[3]\n\n### Catheterization\n\n[Right heart catheterization](Catheterization \"Catheterization\") is the test used to test for elevated diastolic [ventricular pressures](Ventricle_\\(heart\\) \"Ventricle \\(heart\\)\"). This test is more invasive and would be performed after inconclusive [endomyocardial biopsy](Endomyocardial_biopsy \"Endomyocardial biopsy\") samples.[1]\n\n### Cardiac magnetic resonance imaging\n\n[Cardiac magnetic resonance](Cardiac_magnetic_resonance_imaging \"Cardiac magnetic resonance imaging\") (CMR) is capable of measuring the thickness of different areas of the heart. This can be used for quantification of the deposits in the heart.[1] CMR also shows the characterization of [myocardial tissue](Cardiac_muscle \"Cardiac muscle\") through patterns of [gadolinium](Gadolinium \"Gadolinium\") enhancements.[2] However, none of the CMR technique is able to differentiate ATTR-CM and AL-CM definitely.[13]\n\nFor AL-CM, 68% of them have symmetrical and concentric [left ventricular hypertrophy](Left_ventricular_hypertrophy \"Left ventricular hypertrophy\"). On the other hand, for ATTR-CM, 79% of them have asymmetrical left ventricular hypertrophy and 18% of them have symmetrical and concentric left ventricular hypertrophy.[13]\n\nIn [T1-weighted imaging](Magnetic_resonance_imaging#T1_and_T2 \"Magnetic resonance imaging\"), edema in the heart can be detected with a high T1 signal. Meanwhile, enlargement of heart cells will reduce the T1 signal. Using T1 signal, Extracellular volume (ECV) is useful to determine the degree of amyloid deposition around the heart cells and detect the regression of amyloid deposits after treatment. ECV is higher in ATTR-CM than in AL-CM.[13]\n\nIn T2-weighted imaging, the T2 signal is increased in acute myocarditis (inflammation of heart muscles), and [myocardial infarction](Myocardial_infarction \"Myocardial infarction\") (heart attack). T2 signal is also increased in AL-CM and ATTR-CM but the signal is greater in AL-CM before starting chemotherapy.[13]\n\n[Late gadolinum enhancement](Cardiac_magnetic_resonance_imaging#Late_gadolinium_enhancement \"Cardiac magnetic resonance imaging\") (LGE) can determine the severity of deposition of amyloid in heart tissue. The higher the LGE signal, the more severe the heart involvement. It can be divided into three stages: no LGE, sub[endocardial](Endocardium \"Endocardium\") LGE, and full-thickness (transmural) LGE.[13]\n\n### Scintigraphy/radionuclide imaging\n\n[Scintigraphy](Scintigraphy \"Scintigraphy\") can be used to measure the extent and distribution of the amyloid throughout the body, including the liver, kidney, spleen, and heart.[2] A [radiolabelled](Radiolabelled \"Radiolabelled\") serum amyloid P component can be administered to a patient [intravenously](Intravenous_therapy \"Intravenous therapy\") and the P component pools to the amyloid deposit proportional to the size of the deposit. The labeling of the P component can then be pictured by a [gamma camera](Gamma_camera \"Gamma camera\").[1]\n\nTechnetium-labeled bone tracer scintigraphy (e.g., 99mTc-PYP or 99mTc-DPD) can reliably diagnose transthyretin (ATTR) cardiac amyloidosis, with certain scanning methods having greater than 99% sensitivity and approximately 91% specificity when used in patients without monoclonal gammopathy.[](https://doi.org/10.1161/CIRCULATIONAHA.116.021612) In this method, the radiolabeled technetium is injected into the body where it binds preferentially to ATTR amyloid deposits in the heart. A subsequent scan highlights the uptake, graded from 0 to 3, with grade 2-3 uptake in the absence of light-chain amyloidosis allowing non-invasive definitive diagnosis of ATTR-CA (previously requiring endomyocardial biopsy).[14] As of 2025, consensus guidelines reaffirm the role of 99mTc-PYP scintigraphy as a key diagnostic tool for ATTR-CA.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11701493/) Emerging pan-amyloid tracers, such as I-evuzamitide, show promise for broader detection across amyloid types, with early data indicating 100% sensitivity and specificity for cardiac amyloidosis.[](https://attralus.com/press-releases/attralus-presents-new-data-on-its-pan-amyloid-diagnostic-imaging-candidates-at-asnc-2025)\n\n### Mass spectrometry\n\n[Mass spectrometry](Mass_spectrometry \"Mass spectrometry\") can be used to determine whether the protein is light-chain or familial amyloidosis by identifying the [protein subunit](Protein_subunit \"Protein subunit\").[9]\n# Treatments\n\nTreatments differ according to the type of amyloidosis present.[1] The majority of treatment is aimed at preserving heart function and treating heart failure symptoms.[3]\n\n### Light chain (AL-CM) Treatment\nSince the cause of this subtype of cardiac amyloidosis is the excessive production of free light chains, the major goal of treatment is the reduction in concentration of light chains.[5] For light-chain amyloidosis, the use of FLC assays and NT-proBNP levels can be used to monitor the progression of amyloidosis and any response to treatments.[1] One of the major routes to decrease the production of these excess light chains is to kill the abnormal cells that are producing them.[5] Chemotherapeutic agents such as [melphalan](Melphalan \"Melphalan\") or [bortezomib](Bortezomib \"Bortezomib\") can be used to kill off the abnormal cell line that is producing the free light chains.[5] Following chemotherapy, a [bone marrow transplant](Hematopoietic_stem_cell_transplantation \"Hematopoietic stem cell transplantation\") can be utilized to restore the normal cell lines.[5] Medications such as ixazomib, carfilzomib, daratumumab, and elotuzumab are incorporated into standard regimens, including the FDA-approved daratumumab-based quadruplet therapy (daratumumab, cyclophosphamide, bortezomib, and dexamethasone) as first-line treatment for AL amyloidosis since 2021.[](https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-becomes-the-first-fda-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis) New data suggests that orthotopic heart transplant followed by melphalan and stem cell transplant produces results similar to non cardiac amyloidosis indicated heart transplant.[5] To treat complications, medications can be prescribed including [midodrine](Midodrine \"Midodrine\") for [autonomic neuropathy](Autonomic_neuropathy \"Autonomic neuropathy\"), [amiodarone](Amiodarone \"Amiodarone\") for patients with [atrial fibrillation](Atrial_fibrillation \"Atrial fibrillation\") to prevent [arrhythmias](Heart_arrhythmia \"Heart arrhythmia\"), and [warfarin](Warfarin \"Warfarin\") used after a cardioembolic episode.[1]\n\n### Familial (ATTRm-CM) Treatment\nIn recent years there have been developments in the treatment of Familial/Transthyretin cardiac amyloidosis including methods to suppress transthyretin production, stabilize amyloid fibrils, and medications that can destroy already existing fibrils.[6] For familial amyloidosis, [ACE-inhibitors](ACE_inhibitor \"ACE inhibitor\") and beta-blockers can be prescribed if there is no autonomic neuropathy.[1]\n\n- **Suppression of transthyretin production:** liver transplantation and medications that decreases the activity of the transthyretin genes ([patisiran](Patisiran \"Patisiran\"), [inotersen](Inotersen \"Inotersen\"), and [vutrisiran](Vutrisiran \"Vutrisiran\")).[6] Vutrisiran was FDA-approved in March 2025 for ATTR-CM.[](https://investors.alnylam.com/press-release?id=28831) In patients with familial transthyretin mutations, liver transplantation can provide the body with a source of normal transthyretin.[15] By changing the source of transthyretin from the original liver that contains the mutated transthyretin to a healthy liver, there will be no more production of the abnormal protein.[15] However, liver transplant does not reverse the disease.[15] The goal of liver transplant is to prevent additional amyloid deposition and prevent new symptoms/complications from happening.[15] These medications bind to the mRNA of transthyretin and prevent the production of the transthyretin protein, thus decreasing the overall amount of transthyretin that can accumulate in the body.[6]\n- **Stabilization of abnormal transthyretin:** There are medications that can stabilize the normally folded transthyretin, preventing misfolding and subsequent amyloid deposition.[6] These medications include [Tafamidis](Tafamidis \"Tafamidis\"), the [NSAID](NSAID \"NSAID\") [Diflunisal](Diflunisal \"Diflunisal\"), and acoramidis.[6] Tafamidis is a medication that binds to transthyretin and keeps it in its normal shape, stopping it from aggregating into amyloid fibrils.[6] Acoramidis, formerly known as AG10, was FDA-approved in November 2024 for ATTR-CM.[](https://bridgebio.com/news/attruby-acoramidis-a-near-complete-ttr-stabilizer-%25E2%2589%25A590-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-attr-cm-patients/) Diflunisal works in a similar manner to tafamidis in its ability to bind to and stabilize Transthyretin.[16]\n- **Destruction of existing amyloid fibrils:** There are multiple medications that show amyloid destroying properties, [Doxycycline](Doxycycline \"Doxycycline\"), [Tauro-ursodeoxy-cholic acid (TUDCA)](TUDCA \"TUDCA\"), and monoclonal antibodies.[6]\n\n### Wild-type (ATTRwt-CM) Treatment\nTreatments for wild-type transthyretin cardiac amyloidosis primarily focus on stabilizing transthyretin to prevent further amyloid deposition and managing heart failure symptoms, as there is no genetic mutation to target with suppression therapies. TTR stabilizers such as tafamidis (FDA-approved 2019) and acoramidis (FDA-approved 2024) are standard. Gene silencers like vutrisiran (FDA-approved 2025 for ATTR-CM, including wild-type) may also be used to reduce TTR production. Supportive care includes diuretics for congestion, and caution with ACE inhibitors or beta-blockers due to risk of hypotension.[](https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016)\n\nThe use of [pacemakers](Pacemakers \"Pacemakers\") (both right ventricular pacing and biventricular pacing) or [implantable cardioverter defibrillators](Implantable_cardioverter-defibrillator \"Implantable cardioverter-defibrillator\") remains questionable in cardiac amyloidosis.[17]\n## Prognosis\n\nOverall prognosis is dependent on the extent of cardiac dysfunction. Worse outcomes have been seen when echocardiography shows left ventricular wall thickness, poor systolic function and severe diastolic dysfunction.[1]\n\n**Light chain (AL-CM) Prognosis:** For light-chain amyloidosis early detection leads to best possibility of therapies prolonging the period of remission.[3] In contemporary cohorts (as of 2023), median survival is approximately 5 years, with 5-year survival up to 93% in patients achieving cardiac complete response.[5][](https://www.jacc.org/doi/10.1016/j.jaccao.2022.08.009)[](https://ashpublications.org/blood/article/144/7/790/516349/Patients-with-a-cardiac-complete-response-in-AL) In patients that undergo autologous stem cell transplant, median survival can exceed 10 years in responders.[5] Staging systems have been developed to stratify severity of the disease, including the Mayo Biomarker Stage, which utilizes various biomarkers such as troponin I, troponin T, BNP, and NT-proBNP, and free light chain concentrations.[5]\n\n**Familial (ATTRm-CM) Prognosis:** Due to the extensive number of variables involved in this subtype, prognosis varies depending on the specific type of familial cardiac amyloidosis.[5] Variables include the specific TTR mutation versus wild-type ATTR (ATTRwt), and age of onset of symptoms.[5] In comparison to light chain amyloidosis, the ATTR subtypes (both mutant and wild-type) are generally slower to progress and have a more favorable prognosis untreated.[5] However, the Val122Ile mutation (common in individuals of African ancestry) has a median survival of approximately 3.4 years after diagnosis untreated, though treatment with stabilizers like tafamidis improves outcomes.[5][](https://www.myamyloidosisteam.com/resources/whats-the-life-expectancy-with-hattr-amyloidosis) A delay in recognition plays a major factor in reduced survival.[5]\n\n**Wild-type (ATTRwt-CM) Prognosis:** Wild-type transthyretin amyloidosis primarily affects older adults and has a median survival of 3.5 to 5 years from diagnosis if untreated. With tafamidis treatment, 5-year survival is approximately 55% as of 2025.[7][](https://pmc.ncbi.nlm.nih.gov/articles/PMC10607607/)[](https://www.jacc.org/doi/10.1016/j.jaccao.2024.12.005)"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761883475630,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ Fikrle M, PaleÄek T, Kuchynka P, NÄ›meÄek E, BauerovÃ¡ L, Straub J, et al. (2013-02-01). [\\\"Cardiac amyloidosis: A comprehensive review\\\"](https://doi.org/10.1016%2Fj.crvasa.2012.11.018). _Cor et Vasa_. **55** (1): e60 â€“ e75. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.crvasa.2012.11.018](https://doi.org/10.1016%2Fj.crvasa.2012.11.018). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0010-8650](https://search.worldcat.org/issn/0010-8650).\",\"description\":\"1. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ Fikrle M, PaleÄek T, Kuchynka P, NÄ›meÄek E, BauerovÃ¡ L, Straub J, et al. (2013-02-01). [\\\"Cardiac amyloidosis: A comprehensive review\\\"](https://doi.org/10.1016%2Fj.crvasa.2012.11.018). _Cor et Vasa_. **55** (1): e60 â€“ e75. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.crvasa.2012.11.018](https://doi.org/10.1016%2Fj.crvasa.2012.11.018). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0010-8650](https://search.worldcat.org/issn/0010-8650).\",\"url\":\"https://doi.org/10.1016%2Fj.crvasa.2012.11.018\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ _**aa**_ Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD (2012-04-24). [\\\"Updates in Cardiac Amyloidosis: A Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487372). _Journal of the American Heart Association_. **1** (2): e000364. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/JAHA.111.000364](https://doi.org/10.1161%2FJAHA.111.000364). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2047-9980](https://search.worldcat.org/issn/2047-9980). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3487372](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487372). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23130126](https://pubmed.ncbi.nlm.nih.gov/23130126).\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ _**aa**_ Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD (2012-04-24). [\\\"Updates in Cardiac Amyloidosis: A Review\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487372). _Journal of the American Heart Association_. **1** (2): e000364. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/JAHA.111.000364](https://doi.org/10.1161%2FJAHA.111.000364). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2047-9980](https://search.worldcat.org/issn/2047-9980). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3487372](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487372). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23130126](https://pubmed.ncbi.nlm.nih.gov/23130126).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487372\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ Falk RH, Alexander KM, et al. (2016-09-20). [\\\"AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy\\\"](http://www.onlinejacc.org/content/68/12/1323). _Journal of the American College of Cardiology_. **68** (12): 1323â€“1341\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jacc.2016.06.053](https://doi.org/10.1016%2Fj.jacc.2016.06.053). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0735-1097](https://search.worldcat.org/issn/0735-1097). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27634125](https://pubmed.ncbi.nlm.nih.gov/27634125).\",\"description\":\"3. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ Falk RH, Alexander KM, et al. (2016-09-20). [\\\"AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy\\\"](http://www.onlinejacc.org/content/68/12/1323). _Journal of the American College of Cardiology_. **68** (12): 1323â€“1341\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jacc.2016.06.053](https://doi.org/10.1016%2Fj.jacc.2016.06.053). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0735-1097](https://search.worldcat.org/issn/0735-1097). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27634125](https://pubmed.ncbi.nlm.nih.gov/27634125).\",\"url\":\"http://www.onlinejacc.org/content/68/12/1323\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V, et al. (2018-01-01). \\\"Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions\\\". _Current Problems in Cardiology_. **43** (1): 10â€“34\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cpcardiol.2017.04.003](https://doi.org/10.1016%2Fj.cpcardiol.2017.04.003). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0146-2806](https://search.worldcat.org/issn/0146-2806). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29173805](https://pubmed.ncbi.nlm.nih.gov/29173805).\",\"description\":\"4. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V, et al. (2018-01-01). \\\"Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions\\\". _Current Problems in Cardiology_. **43** (1): 10â€“34\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cpcardiol.2017.04.003](https://doi.org/10.1016%2Fj.cpcardiol.2017.04.003). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0146-2806](https://search.worldcat.org/issn/0146-2806). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29173805](https://pubmed.ncbi.nlm.nih.gov/29173805).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ Siddiqi OK, Ruberg FL (January 2018). [\\\"Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741539). _Trends in Cardiovascular Medicine_. **28** (1): 10â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.tcm.2017.07.004](https://doi.org/10.1016%2Fj.tcm.2017.07.004). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1873-2615](https://search.worldcat.org/issn/1873-2615). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5741539](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741539). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28739313](https://pubmed.ncbi.nlm.nih.gov/28739313).\",\"description\":\"5. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ Siddiqi OK, Ruberg FL (January 2018). [\\\"Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741539). _Trends in Cardiovascular Medicine_. **28** (1): 10â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.tcm.2017.07.004](https://doi.org/10.1016%2Fj.tcm.2017.07.004). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1873-2615](https://search.worldcat.org/issn/1873-2615). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5741539](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741539). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28739313](https://pubmed.ncbi.nlm.nih.gov/28739313).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741539\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ Manolis AS, Manolis AA, Manolis TA, Melita H (September 2019). [\\\"Cardiac amyloidosis: An underdiagnosed/underappreciated disease\\\"](https://dx.doi.org/10.1016/j.ejim.2019.07.022). _European Journal of Internal Medicine_. **67** : 1â€“13\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ejim.2019.07.022](https://doi.org/10.1016%2Fj.ejim.2019.07.022). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0953-6205](https://search.worldcat.org/issn/0953-6205). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31375251](https://pubmed.ncbi.nlm.nih.gov/31375251). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [199388460](https://api.semanticscholar.org/CorpusID:199388460).\",\"description\":\"6. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ Manolis AS, Manolis AA, Manolis TA, Melita H (September 2019). [\\\"Cardiac amyloidosis: An underdiagnosed/underappreciated disease\\\"](https://dx.doi.org/10.1016/j.ejim.2019.07.022). _European Journal of Internal Medicine_. **67** : 1â€“13\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ejim.2019.07.022](https://doi.org/10.1016%2Fj.ejim.2019.07.022). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0953-6205](https://search.worldcat.org/issn/0953-6205). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31375251](https://pubmed.ncbi.nlm.nih.gov/31375251). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [199388460](https://api.semanticscholar.org/CorpusID:199388460).\",\"url\":\"https://dx.doi.org/10.1016/j.ejim.2019.07.022\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Ruberg FL, Berk JL (2012-09-04). [\\\"Transthyretin (TTR) Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501197). _Circulation_. **126** (10): 1286â€“1300\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/CIRCULATIONAHA.111.078915](https://doi.org/10.1161%2FCIRCULATIONAHA.111.078915). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0009-7322](https://search.worldcat.org/issn/0009-7322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3501197](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501197). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22949539](https://pubmed.ncbi.nlm.nih.gov/22949539).\",\"description\":\"7. ^ _**a**_ _**b**_ _**c**_ _**d**_ Ruberg FL, Berk JL (2012-09-04). [\\\"Transthyretin (TTR) Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501197). _Circulation_. **126** (10): 1286â€“1300\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/CIRCULATIONAHA.111.078915](https://doi.org/10.1161%2FCIRCULATIONAHA.111.078915). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0009-7322](https://search.worldcat.org/issn/0009-7322). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3501197](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501197). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22949539](https://pubmed.ncbi.nlm.nih.gov/22949539).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501197\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"_**a**_ _**b**_ _**c**_ Falk RH, Comenzo RL, et al. (25 September 1997). \\\"The Systemic Amyloidoses\\\". _New England Journal of Medicine_. **337** (13): 898â€“909\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJM199709253371306](https://doi.org/10.1056%2FNEJM199709253371306). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9302305](https://pubmed.ncbi.nlm.nih.gov/9302305).\",\"description\":\"8. ^ _**a**_ _**b**_ _**c**_ Falk RH, Comenzo RL, et al. (25 September 1997). \\\"The Systemic Amyloidoses\\\". _New England Journal of Medicine_. **337** (13): 898â€“909\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJM199709253371306](https://doi.org/10.1056%2FNEJM199709253371306). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9302305](https://pubmed.ncbi.nlm.nih.gov/9302305).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ Gertz MA, Dispenzieri A, Sher T (2014-10-14). \\\"Pathophysiology and treatment of cardiac amyloidosis\\\". _Nature Reviews Cardiology_. **12** (2): 91â€“102\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrcardio.2014.165](https://doi.org/10.1038%2Fnrcardio.2014.165). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1759-5002](https://search.worldcat.org/issn/1759-5002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25311231](https://pubmed.ncbi.nlm.nih.gov/25311231). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [2080325](https://api.semanticscholar.org/CorpusID:2080325).\",\"description\":\"9. ^ _**a**_ _**b**_ Gertz MA, Dispenzieri A, Sher T (2014-10-14). \\\"Pathophysiology and treatment of cardiac amyloidosis\\\". _Nature Reviews Cardiology_. **12** (2): 91â€“102\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrcardio.2014.165](https://doi.org/10.1038%2Fnrcardio.2014.165). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1759-5002](https://search.worldcat.org/issn/1759-5002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25311231](https://pubmed.ncbi.nlm.nih.gov/25311231). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [2080325](https://api.semanticscholar.org/CorpusID:2080325).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Clemmensen TS, Soerensen J, Hansson N, Tolbod LP, Harms HJ, EiskjÃ¦r H, et al. (2018-11-06). [\\\"Myocardial Oxygen Consumption and Efficiency in Patients With Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404209). _Journal of the American Heart Association_. **7** (21): e009974. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/JAHA.118.009974](https://doi.org/10.1161%2FJAHA.118.009974). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2047-9980](https://search.worldcat.org/issn/2047-9980). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6404209](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404209). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30571379](https://pubmed.ncbi.nlm.nih.gov/30571379).\",\"description\":\"10. **^** Clemmensen TS, Soerensen J, Hansson N, Tolbod LP, Harms HJ, EiskjÃ¦r H, et al. (2018-11-06). [\\\"Myocardial Oxygen Consumption and Efficiency in Patients With Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404209). _Journal of the American Heart Association_. **7** (21): e009974. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/JAHA.118.009974](https://doi.org/10.1161%2FJAHA.118.009974). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2047-9980](https://search.worldcat.org/issn/2047-9980). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6404209](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404209). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30571379](https://pubmed.ncbi.nlm.nih.gov/30571379).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404209\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Hartnett, Jack; Jaber, Wael; Maurer, Mathew; Sperry, Brett; Hanna, Mazen; Collier, Patrick; Patel, Divyang R.; Wazni, Oussama M.; Donnellan, Eoin (October 2021). [\\\"Electrophysiological Manifestations of Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543134). _JACC: CardioOncology_. **3** (4): 506â€“515\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jaccao.2021.07.010](https://doi.org/10.1016%2Fj.jaccao.2021.07.010). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8543134](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543134). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34729522](https://pubmed.ncbi.nlm.nih.gov/34729522). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [239554406](https://api.semanticscholar.org/CorpusID:239554406).\",\"description\":\"11. **^** Hartnett, Jack; Jaber, Wael; Maurer, Mathew; Sperry, Brett; Hanna, Mazen; Collier, Patrick; Patel, Divyang R.; Wazni, Oussama M.; Donnellan, Eoin (October 2021). [\\\"Electrophysiological Manifestations of Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543134). _JACC: CardioOncology_. **3** (4): 506â€“515\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jaccao.2021.07.010](https://doi.org/10.1016%2Fj.jaccao.2021.07.010). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8543134](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543134). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [34729522](https://pubmed.ncbi.nlm.nih.gov/34729522). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [239554406](https://api.semanticscholar.org/CorpusID:239554406).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543134\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"_**a**_ _**b**_ Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, et al. (December 2018). [\\\"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278059). _BMC Cardiovascular Disorders_. **18** (1) 221. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s12872-018-0952-8](https://doi.org/10.1186%2Fs12872-018-0952-8). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1471-2261](https://search.worldcat.org/issn/1471-2261). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6278059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278059). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30509186](https://pubmed.ncbi.nlm.nih.gov/30509186).\",\"description\":\"12. ^ _**a**_ _**b**_ Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, et al. (December 2018). [\\\"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278059). _BMC Cardiovascular Disorders_. **18** (1) 221. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s12872-018-0952-8](https://doi.org/10.1186%2Fs12872-018-0952-8). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1471-2261](https://search.worldcat.org/issn/1471-2261). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6278059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278059). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30509186](https://pubmed.ncbi.nlm.nih.gov/30509186).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278059\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M (July 2020). [\\\"Diagnostic imaging of cardiac amyloidosis\\\"](http://www.nature.com/articles/s41569-020-0334-7). _Nature Reviews Cardiology_. **17** (7): 413â€“426\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41569-020-0334-7](https://doi.org/10.1038%2Fs41569-020-0334-7). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1759-5002](https://search.worldcat.org/issn/1759-5002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32042139](https://pubmed.ncbi.nlm.nih.gov/32042139). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [211067205](https://api.semanticscholar.org/CorpusID:211067205).\",\"description\":\"13. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M (July 2020). [\\\"Diagnostic imaging of cardiac amyloidosis\\\"](http://www.nature.com/articles/s41569-020-0334-7). _Nature Reviews Cardiology_. **17** (7): 413â€“426\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41569-020-0334-7](https://doi.org/10.1038%2Fs41569-020-0334-7). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1759-5002](https://search.worldcat.org/issn/1759-5002). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32042139](https://pubmed.ncbi.nlm.nih.gov/32042139). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [211067205](https://api.semanticscholar.org/CorpusID:211067205).\",\"url\":\"http://www.nature.com/articles/s41569-020-0334-7\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. (2016-06-14). [\\\"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis\\\"](https://doi.org/10.1161%2FCIRCULATIONAHA.116.021612). _Circulation_. **133** (24): 2404â€“2412\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/CIRCULATIONAHA.116.021612](https://doi.org/10.1161%2FCIRCULATIONAHA.116.021612). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[11392/2415152](https://hdl.handle.net/11392%2F2415152). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0009-7322](https://search.worldcat.org/issn/0009-7322). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27143678](https://pubmed.ncbi.nlm.nih.gov/27143678). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [7106253](https://api.semanticscholar.org/CorpusID:7106253).\",\"description\":\"14. ^ _**a**_ _**b**_ _**c**_ _**d**_ Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. (2016-06-14). [\\\"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis\\\"](https://doi.org/10.1161%2FCIRCULATIONAHA.116.021612). _Circulation_. **133** (24): 2404â€“2412\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1161/CIRCULATIONAHA.116.021612](https://doi.org/10.1161%2FCIRCULATIONAHA.116.021612). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[11392/2415152](https://hdl.handle.net/11392%2F2415152). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [0009-7322](https://search.worldcat.org/issn/0009-7322). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27143678](https://pubmed.ncbi.nlm.nih.gov/27143678). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [7106253](https://api.semanticscholar.org/CorpusID:7106253).\",\"url\":\"https://doi.org/10.1161%2FCIRCULATIONAHA.116.021612\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Rocha A, Lobato L (April 2015). [\\\"Reply: Liver transplantation in transthyretin amyloidosis: Issues and challenges\\\"](https://dx.doi.org/10.1002/lt.24150). _Liver Transplantation_ : n/a. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/lt.24150](https://doi.org/10.1002%2Flt.24150). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-6465](https://search.worldcat.org/issn/1527-6465). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25891323](https://pubmed.ncbi.nlm.nih.gov/25891323).\",\"description\":\"15. ^ _**a**_ _**b**_ _**c**_ _**d**_ Rocha A, Lobato L (April 2015). [\\\"Reply: Liver transplantation in transthyretin amyloidosis: Issues and challenges\\\"](https://dx.doi.org/10.1002/lt.24150). _Liver Transplantation_ : n/a. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/lt.24150](https://doi.org/10.1002%2Flt.24150). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1527-6465](https://search.worldcat.org/issn/1527-6465). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25891323](https://pubmed.ncbi.nlm.nih.gov/25891323).\",\"url\":\"https://dx.doi.org/10.1002/lt.24150\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, [Connors LH](Lawreen_Connors \\\"Lawreen Connors\\\"), et al. (September 2020). [\\\"Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758872). _Journal of Cardiac Failure_. **26** (9): 753â€“759\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cardfail.2019.11.024](https://doi.org/10.1016%2Fj.cardfail.2019.11.024). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1532-8414](https://search.worldcat.org/issn/1532-8414). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7758872](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758872). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31805416](https://pubmed.ncbi.nlm.nih.gov/31805416).\",\"description\":\"16. **^** Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, [Connors LH](Lawreen_Connors \\\"Lawreen Connors\\\"), et al. (September 2020). [\\\"Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758872). _Journal of Cardiac Failure_. **26** (9): 753â€“759\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cardfail.2019.11.024](https://doi.org/10.1016%2Fj.cardfail.2019.11.024). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1532-8414](https://search.worldcat.org/issn/1532-8414). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7758872](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758872). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31805416](https://pubmed.ncbi.nlm.nih.gov/31805416).\",\"url\":\"Lawreen_Connors \\\"Lawreen Connors\\\"\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK (March 2020). \\\"Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment\\\". _The Canadian Journal of Cardiology_. **36** (3): 416â€“423\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cjca.2019.11.039](https://doi.org/10.1016%2Fj.cjca.2019.11.039). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1916-7075](https://search.worldcat.org/issn/1916-7075). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32145868](https://pubmed.ncbi.nlm.nih.gov/32145868). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [212638552](https://api.semanticscholar.org/CorpusID:212638552).\",\"description\":\"17. **^** Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK (March 2020). \\\"Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment\\\". _The Canadian Journal of Cardiology_. **36** (3): 416â€“423\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cjca.2019.11.039](https://doi.org/10.1016%2Fj.cjca.2019.11.039). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1916-7075](https://search.worldcat.org/issn/1916-7075). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32145868](https://pubmed.ncbi.nlm.nih.gov/32145868). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [212638552](https://api.semanticscholar.org/CorpusID:212638552).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Baum, Dan (February 29, 2012). [\\\"No Pulse: How Doctors Reinvented The Human Heart\\\"](https://www.popsci.com/science/article/2012-02/no-pulse-how-doctors-reinvented-human-heart/). [Popular Science](Popular_Science \\\"Popular Science\\\"). Retrieved February 16, 2021.\",\"description\":\"18. **^** Baum, Dan (February 29, 2012). [\\\"No Pulse: How Doctors Reinvented The Human Heart\\\"](https://www.popsci.com/science/article/2012-02/no-pulse-how-doctors-reinvented-human-heart/). [Popular Science](Popular_Science \\\"Popular Science\\\"). Retrieved February 16, 2021.\",\"url\":\"https://www.popsci.com/science/article/2012-02/no-pulse-how-doctors-reinvented-human-heart/\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Cardiac amyloidosis has multiple sub-types including light chain, familial, and senile.[3]\",\"explanation\":\"The terminology \\\"senile\\\" for the wild-type form of transthyretin amyloidosis is outdated; current standard is wild-type transthyretin (ATTRwt). \\\"Familial\\\" is now specified as hereditary or mutant transthyretin (ATTRm). This misstates the current classification used in medical literature.\",\"fixedText\":\"Update subtypes to: light chain (AL), hereditary transthyretin (ATTRm), and wild-type transthyretin (ATTRwt).\",\"evidenceSource\":\"Web search: Johns Hopkins Medicine, Cleveland Clinic (2025 updates)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"New treatment methods are actively being researched in regards to the treatment of heart failure and specific cardiac amyloidosis problems.[5][6]\",\"explanation\":\"As of 2025, multiple disease-modifying treatments have been FDA-approved, including tafamidis (2019) and acoramidis (2024) for ATTR-CM, and advances like daratumumab combinations for AL amyloidosis. The claim implies a lack of established therapies, which is no longer accurate.\",\"fixedText\":\"Revise to reflect approved treatments and ongoing research: \\\"Disease-modifying treatments targeting amyloid production have been approved for AL and ATTR types, with ongoing research into additional therapies for heart failure and disease progression.[](https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016)\\\"\",\"evidenceSource\":\"[](https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The introduction lacks current context on the prevalence and recognition of cardiac amyloidosis, particularly that ATTR-CM is now recognized as a common cause of heart failure in older adults, affecting an estimated 200,000â€“300,000 globally for ATTRwt as of 2025. This gap hinders understanding of its scope and significance.\",\"fixedText\":\"Add a sentence: \\\"It is increasingly recognized, particularly the transthyretin (ATTR) forms, which are prevalent in older adults and contribute significantly to heart failure with preserved ejection fraction.\\\"\",\"evidenceSource\":\"[](https://www.mdpi.com/2077-0383/14/13/4785)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"This type is considered the wild-type mutation which leads to the development of [TTR deposits](Transthyretin \\\"Transthyretin\\\").[2]\",\"explanation\":\"Wild-type ATTR-CM is not caused by a mutation; it involves age-related misfolding of the normal (wild-type) transthyretin protein, unlike ATTRm which has genetic mutations.\",\"fixedText\":\"Change to: \\\"This type involves the wild-type (non-mutated) transthyretin protein that misfolds and forms deposits.\\\"\",\"evidenceSource\":\"Ref 2 (2012) is outdated; current sources like StatPearls (2025) confirm wild-type ATTR is non-mutated TTR.\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"For the diagnosis of familial cardiac amyloidosis to be made a biopsy with histological evaluation must be obtained.[7]\",\"explanation\":\"Current guidelines (as of 2025) allow non-invasive diagnosis of ATTRm-CM using Tc-99m-PYP/DPD scintigraphy (grade 2-3 uptake) combined with genetic testing confirming a pathogenic TTR mutation, without needing biopsy if AL is ruled out. The cited ref 7 (2012) predates this standard.\",\"fixedText\":\"Revise to: \\\"Diagnosis can often be made non-invasively with genetic testing for TTR mutations and positive cardiac scintigraphy; biopsy is reserved for equivocal cases or to rule out AL.\\\"\",\"evidenceSource\":\"ACC Expert Consensus (2023); StatPearls (2025) []https://www.ncbi.nlm.nih.gov/books/NBK580521/); Gillmore et al. (2016, ref 14)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Similar to the other subtypes of cardiac amyloidosis, a biopsy is required for diagnosis.[4]\",\"explanation\":\"For ATTRwt-CM, biopsy is not always required; non-invasive diagnosis is standard using scintigraphy (grade 2-3 uptake) with absence of monoclonal proteins and no TTR mutation. Ref 4 (2018) is partially outdated post-2016 non-biopsy criteria.\",\"fixedText\":\"Revise to: \\\"Diagnosis can be made non-invasively with cardiac scintigraphy showing grade 2 or 3 uptake and absence of monoclonal proteins; it is a diagnosis of exclusion after ruling out AL and hereditary ATTR.\\\"\",\"evidenceSource\":\"Gillmore et al. (2016, ref 14); AHA Statement (2020) []https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792); Mayo Clinic (2025) []https://www.mayoclinic.org/diseases-conditions/amyloidosis/diagnosis-treatment/drc-20353183)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire diagnostic sentences in subtypes, e.g., in Wild-type: However, formal diagnosis of Senile cardiac amyloidosis is a diagnosis of exclusion.[4] Biopsy with histological evaluation can rule out Light chain and Familial subtypes, leaving the diagnosis of Senile.[4]]\",\"explanation\":\"The section lacks mention of key modern non-invasive tools like bone-avid scintigraphy (Tc-99m-PYP or DPD scans), which are essential for diagnosing ATTR-CM types without biopsy, as per current (2025) guidelines. This creates knowledge gap on diagnostic evolution.\",\"fixedText\":\"Add brief mention of scintigraphy for ATTR types, avoiding duplication with Diagnosis section: e.g., \\\"Non-invasive imaging such as Tc-99m bone scintigraphy is pivotal for ATTR diagnosis.\\\"\",\"evidenceSource\":\"2023 ACC Expert Consensus []https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022); Recent review (2025) []https://link.springer.com/article/10.1007/s12170-025-00771-y)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch | Scope/Applicability Misstatement\",\"problematicText\":\"Symmetric sensory neuropathy (such as bilateral carpal tunnel)[3]\",\"explanation\":\"Bilateral carpal tunnel syndrome is primarily associated with ATTR amyloidosis (both hereditary and wild-type), not AL (light-chain) amyloidosis. Reference [3] (Falk et al., 2016) describes symmetric sensory neuropathy in AL as predominantly affecting lower limbs (e.g., numbness, paresthesias), but does not mention carpal tunnel as an example. Misstating this could mislead clinical diagnosis by associating a key ATTR red flag with AL.\",\"fixedText\":\"Revise to: \\\"Symmetric sensory neuropathy (e.g., painful paresthesias in the lower limbs or hands)\\\" to accurately reflect AL manifestations per [3]. Retain citation [3].\",\"evidenceSource\":\"[3] and https://www.jacc.org/doi/10.1016/j.jacc.2016.06.053; also web search results confirming CTS prevalence in ATTR (up to 50%) vs rare in AL.\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"Loss of the third and fourth heart sound[3] (listed under extracardiac manifestations)\",\"explanation\":\"This is a cardiac auscultatory finding due to myocardial infiltration, not an extracardiac manifestation. Placing it under AL-specific extracardiac symptoms misclassifies it, potentially confusing the distinction between cardiac and systemic involvement. Reference [3] confirms S3 and S4 are uncommon/absent in cardiac amyloidosis generally.\",\"fixedText\":\"Move to the cardiac manifestations bullet list as a general finding, e.g., under auscultation or arrhythmias, with citation [3].\",\"evidenceSource\":\"[3] and https://www.jacc.org/doi/10.1016/j.jacc.2016.06.053\"},{\"criticality\":\"Missing Information\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention\",\"explanation\":\"The section focuses heavily on AL extracardiac symptoms but omits key type-specific differences, such as carpal tunnel syndrome and lumbar spinal stenosis being common early signs in ATTR-CM (both ATTRm and ATTRwt), which can precede cardiac symptoms by years. This creates a knowledge gap given the article's \\\"Types\\\" subsections cover AL-CM, ATTRm-CM, and ATTRwt-CM; brief mention here would aid completeness without duplication.\",\"fixedText\":\"Add a brief paragraph or bullet under extracardiac: \\\"In ATTR amyloidosis, common extracardiac features include bilateral carpal tunnel syndrome and lumbar spinal stenosis, often preceding cardiac involvement.[](https://www.jacc.org/doi/10.1016/j.jacc.2019.04.054)\\\"\",\"evidenceSource\":\"Web search: CTS in up to 50% of ATTR cases (e.g., https://www.jacc.org/doi/10.1016/j.jacc.2019.04.054); spinal stenosis in ATTR (e.g., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222048/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Technetium radionuclide scans can now reliably diagnosis cardiac amyloidosis, with certain scanning methods having greater than 99% sensitivity (but only 91% specific for amyloidosis).[14]\",\"explanation\":\"Reference 14 specifically addresses non-biopsy diagnosis of transthyretin (ATTR) cardiac amyloidosis using technetium-labeled bone tracers like 99mTc-PYP or DPD. These scans show avid uptake in ATTR-CA but minimal uptake in AL amyloidosis, making them unsuitable for diagnosing cardiac amyloidosis in general. The high sensitivity and specificity apply to ATTR-CA when combined with tests ruling out monoclonal gammopathy.\",\"fixedText\":\"Clarify that technetium bone scintigraphy is highly sensitive and specific (\u003e99% sensitivity, ~91% specificity in appropriate contexts) for diagnosing ATTR cardiac amyloidosis, enabling non-invasive confirmation when monoclonal proteins are absent. Mention the 2025 consensus update on its use.\",\"evidenceSource\":\"[14]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"which is 90â€“95% sensitive and 80â€“85% specific for cardiac amyloidosis.[4]\",\"explanation\":\"Reference 4 (Bhogal et al., 2018) discusses echocardiography in cardiac amyloidosis but does not provide these specific sensitivity and specificity values for the relative apical sparing pattern of longitudinal strain.\",\"fixedText\":\"Replace citation with a supporting source, such as Phelan et al. (2012), which reports 93% sensitivity and 82% specificity for the apical sparing pattern in differentiating cardiac amyloidosis from other causes of left ventricular hypertrophy. Adjust numbers accordingly for accuracy.\",\"evidenceSource\":\"[4]\"},{\"criticality\":\"Missing Information\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section does not include recent updates on diagnostic imaging as of 2025, such as the consensus guidelines for 99mTc-pyrophosphate scintigraphy in ATTR-CA or emerging pan-amyloid imaging agents like I-evuzamitide, which showed 100% sensitivity/specificity in early studies.\",\"fixedText\":\"Add a brief note in the Scintigraphy subsection on the 2025 consensus for Tc-PYP scans and mention investigational pan-amyloid tracers for future directions.\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11701493/) [](https://attralus.com/press-releases/attralus-presents-new-data-on-its-pan-amyloid-diagnostic-imaging-candidates-at-asnc-2025)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"There are newer medications (ixazomib, carfilzomib, daratumumab, elotuzumab) under research for the treatment of multiple myeloma that can help to decrease the production of free light chains.\\\"\",\"explanation\":\"Daratumumab was FDA-approved in 2021 for newly diagnosed AL amyloidosis in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) as first-line therapy; ixazomib and carfilzomib are also incorporated into standard regimens for AL-CM, not merely under research as of 2025.\",\"fixedText\":\"Update to reflect approved status and standard use in AL-CM treatment regimens, e.g., daratumumab-based quadruplet therapy as first-line.\",\"evidenceSource\":\"[](https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-becomes-the-first-fda-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"These medications include Tafamidis, the NSAID Diflunisal, and AG10.\\\"\",\"explanation\":\"AG10 has been renamed acoramidis and FDA-approved in November 2024 for ATTR-CM to reduce cardiovascular death and hospitalization; tafamidis was approved in 2019.\",\"fixedText\":\"Replace \\\"AG10\\\" with \\\"acoramidis\\\" and note its 2024 FDA approval for ATTR-CM.\",\"evidenceSource\":\"[](https://bridgebio.com/news/attruby-acoramidis-a-near-complete-ttr-stabilizer-%25E2%2589%25A590-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-attr-cm-patients/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention or subsection for wild-type ATTR-CM treatments.\",\"explanation\":\"The article structure lists \\\"Wild-type (ATTRwt-CM)\\\" as a distinct subtype under Types, but the Treatments section omits dedicated coverage; wt ATTR-CM treatments differ from hereditary (no gene suppression primarily, though recent approvals like vutrisiran apply to both) and focus on TTR stabilization (tafamidis, acoramidis) and symptom management, representing a knowledge gap in comprehensive type-specific treatment discussion.\",\"fixedText\":\"Add a subsection \\\"**Wild-type (ATTRwt-CM) Treatment:**\\\" mirroring the structure for other types, covering TTR stabilizers (tafamidis, acoramidis), emerging gene silencers like vutrisiran (approved 2025 for both wt and hereditary ATTR-CM), and supportive care.\",\"evidenceSource\":\"[](https://www.jacc.org/doi/10.1016/j.jacc.2025.04.016)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No mention of vutrisiran in suppression of transthyretin production.\",\"explanation\":\"Vutrisiran (Amvuttra) was FDA-approved in March 2025 for ATTR-CM (both wild-type and hereditary), providing an additional siRNA option for TTR silencing beyond patisiran and inotersen, which were primarily for polyneuropathy; this is a recent development up to 2025 not covered in the section.\",\"fixedText\":\"Add vutrisiran to the suppression subsection as an approved siRNA therapeutic for ATTR-CM, citing its 2025 approval.\",\"evidenceSource\":\"[](https://investors.alnylam.com/press-release?id=28831)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"Variables involve mutant vs wild type transthyretin mutation\",\"explanation\":\"Wild-type transthyretin (ATTRwt) is the non-mutated form and is not a type of mutation; familial ATTR (ATTRm) involves specific genetic mutations in the TTR gene. This misrepresents the classification of ATTR subtypes.\",\"fixedText\":\"Correct to: \\\"Variables include the specific TTR mutation (for ATTRm) versus wild-type ATTR (ATTRwt), and age of onset of symptoms.\\\"\",\"evidenceSource\":\"Ref 5; [](https://pmc.ncbi.nlm.nih.gov/articles/PMC5741539/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No mention of wild-type ATTRwt-CM prognosis\",\"explanation\":\"The article structure lists Wild-type (ATTRwt-CM) as a distinct type, but the Prognosis section omits it, creating a knowledge gap in covering all major subtypes.\",\"fixedText\":\"Add a subsection for **Wild-type (ATTRwt-CM) Prognosis:** including median survival of approximately 3.5 to 5 years untreated, improved with stabilizers like tafamidis.\",\"evidenceSource\":\"Article structure; [](https://pmc.ncbi.nlm.nih.gov/articles/PMC10607607/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Well treated light chain cardiac amyloidosis has a 4-year survival rate of around 90%.[5] ... Val 122lle mutation ... has a 4-year survival rate of 16% with an average length of 26 months.[5]\",\"explanation\":\"These rates are based on 2018 data (ref 5); as of 2025, new treatments (e.g., tafamidis for ATTR approved 2019, daratumumab for AL) have improved survival. For AL, contemporary cohorts show median ~5 years overall, up to 93% 5-year for responders. For ATTR-CM, 5-year survival ~70% in recent cohorts. Undated presentation implies current status, affecting correctness.\",\"fixedText\":\"Update with recent data, add \\\"as of 2023-2025\\\" or cite new sources, e.g., for AL: median survival ~5 years in contemporary cohorts; for V122I/ATTRm: note improvements with therapy, average ~3.4 years untreated but better with treatment.\",\"evidenceSource\":\"Ref 5; [](https://www.jacc.org/doi/10.1016/j.jaccao.2022.08.009); [](https://www.ahajournals.org/doi/10.1161/JAHA.123.033478); [](https://ashpublications.org/blood/article/144/7/790/516349/Patients-with-a-cardiac-complete-response-in-AL)\"}],\"slug\":\"Cardiac_amyloidosis\",\"title\":\"Cardiac amyloidosis\",\"content\":\"$1f\",\"description\":\"Cardiac amyloidosis\\n\\nis a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues.\",\"metadata\":{\"categories\":[\"amyloid cardiomyopathy\",\"heart amyloidosis\",\"cardiac amyloid\"],\"lastModified\":\"1761553480\",\"contentLength\":\"25100\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"59459\",\"recentViews\":\"59459\",\"dailyAvgViews\":1981.9666748046875,\"qualityScore\":1,\"lastViewed\":\"1761883475\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761883475628,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Cardiac_amyloidosis\"],\"queryHash\":\"[\\\"page\\\",\\\"Cardiac_amyloidosis\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Cardiac amyloidosis\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"is a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart's atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.[1] The overall decrease in cardiac function leads to a plethora of symptoms.[2] This multisystem disease was often misdiagnosed, with a corrected...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"amyloid cardiomyopathy, heart amyloidosis, cardiac amyloid\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Cardiac_amyloidosis\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Cardiac amyloidosis\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"is a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart's atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.[1] The overall decrease in cardiac function leads to a plethora of symptoms.[2] This multisystem disease was often misdiagnosed, with a corrected...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Cardiac_amyloidosis\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Cardiac amyloidosis\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.480Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Cardiac amyloidosis\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"is a subcategory of amyloidosis where there is depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart's atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function.[1] The overall decrease in cardiac function leads to a plethora of symptoms.[2] This multisystem disease was often misdiagnosed, with a corrected...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZTZmYjkxMTMtZjNhMS00YjczLWExNGQtZDczYmQ1MWUwYWZh">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Cardiac_amyloidosis\"}]}]\n"])</script></body></html>